Biofrontera (NASDAQ:BFRI – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Friday, May 13th. Analysts expect Biofrontera to post earnings of ($0.16) per share for the quarter. Biofrontera has set its FY 2022 guidance at EPS.
Biofrontera (NASDAQ:BFRI – Get Rating) last issued its earnings results on Friday, April 8th. The company reported ($0.42) earnings per share for the quarter. The business had revenue of $9.17 million for the quarter. On average, analysts expect Biofrontera to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Biofrontera stock opened at $3.48 on Friday. Biofrontera has a fifty-two week low of $2.20 and a fifty-two week high of $14.63. The company has a 50 day moving average of $3.38.
Separately, Zacks Investment Research lowered shares of Biofrontera from a “buy” rating to a “hold” rating in a research report on Tuesday, March 15th.
Biofrontera Company Profile (Get Rating)
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
- Get a free copy of the StockNews.com research report on Biofrontera (BFRI)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.